Bavarian Nordic Announces Commercial Launch of Mpox Vaccine in the U.S.
Bavarian Nordic A/S (OMX: BAVA) announced today that JYNNEOS®, the only FDA-approved mpox vaccine, is now commercially a…
Bavarian Nordic A/S (OMX: BAVA) announced today that JYNNEOS®, the only FDA-approved mpox vaccine, is now commercially a…
Bavarian Nordic A/S (OMX: BAVA) announced today that the Swiss Agency for Therapeutic Products, Swissmedic, has approved…
BSI Life Sciences announces Harmony Clinical Research (HarmonyCR) as the latest client to adopt its cloud-based electron…
Infektionen mit dem Hepatitis-E-Virus (HEV) werden immer relevanter für die weltweite öffentliche Gesundheit.1,2 Roc…
Bavarian Nordic A/S (OMX: BAVA) announced today its interim financial results for the first nine months of 2023 and busi…
New partnership will harness Moderna’s mRNA rapid-response platform, clinically validated during the COVID-19 pandemic,…
Messenger RNA (mRNA) nanomedicines, a ground-breaking technology that has led to the development of the first approved C…
. New agreement to establish global commercial manufacturing capacity for Vaxcyte's PCV candidates, VAX-24 and VAX-31,…
Bavarian Nordic A/S (OMX: BAVA) announced today, that it has been awarded another contract valued at more than EUR 11 mi…
The International Congress on Particle Technology (PARTEC) will take place in Nuremberg from 26-28 September 2023. This…